PDCD1 and hepatocellular carcinoma: Fourth, large number of patients lost lab test (n = 21) may resulted in bias, yet the clinical data of enrolled patients is complete, and we observed that the incidence of RIHT in patients with HCC treated with RT plus anti-PD1 was acceptable and similar to that of patients treated with RT alone.